Epigenetic Age Acceleration Enhances Prediction Of Overall Survival In Early-Stage Non-Small Cell Lung Cancer
Imagine if a simple blood test could give doctors a clearer picture of how a patient with early-stage lung cancer might fare, even better than knowing their smoking history. Recent research suggests this could be a reality by looking at something called “epigenetic age acceleration.”
Our bodies have a chronological age, which is how many years we’ve been alive. But we also have a “biological age,” which reflects the true age of our cells and tissues. Scientists can measure this biological age using “epigenetic clocks,” which are molecular tools that analyze patterns of chemical tags on our DNA, called methylation. These tags influence how our genes are expressed without changing the underlying genetic code.
This study found that how quickly a person’s biological age is advancing compared to their chronological age—a phenomenon called epigenetic age acceleration—is a powerful indicator of survival in early-stage non-small cell lung cancer. One particular epigenetic clock, named GrimAge2, proved to be exceptionally good at this prediction. In fact, it was a more significant predictor of survival than even a patient’s smoking history, which has traditionally been a key factor.
The findings showed that patients who experienced a faster biological aging process tended to have shorter survival times, while those whose biological aging was slower lived longer. This suggests that the GrimAge2 clock is picking up on crucial biological signals related to lung cancer survival that go beyond what we can learn from smoking history alone. This breakthrough could pave the way for more personalized treatment plans and potentially improve outcomes for individuals battling early-stage lung cancer.
Source: link to paper